AC Immune Q2 results: Strong immunogenicity in Parkinson's disease trial, cash resources to Q1 2027.

• AC Immune reports Q2 2025 financial results • Three active immunotherapies for neurodegeneration in Phase 2 development • Strong immunogenicity and favorable safety profile in Parkinson's disease trial • Alzheimer's disease trial to reach 12 months of treatment in December 2025 • Small molecule NLRP3 program in IND-enabling studies • Cash resources of CHF 127.1 million as of June 30, 2025 • Funding into Q1 2027 excluding potential milestone payments

AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, reported its second-quarter 2025 financial results and provided a corporate update on August 5, 2025. The company highlighted progress in its pipeline and robust financial position.

Financial Highlights:
- Cash Resources: AC Immune reported a cash balance of CHF 127.1 million (USD 157.6 million) as of June 30, 2025, providing funding into Q1 2027, excluding potential milestone payments [1].
- Contract Revenues: The company recorded CHF 1.3 million in contract revenues for the three months ended June 30, 2025, compared to CHF 0.7 million in the comparable prior period [1].
- R&D Expenditures: Research and development expenses for the quarter were CHF 16.8 million, a decrease from CHF 17.1 million in the same period in 2024 [1].
- G&A Expenditures: General and administrative expenses decreased by CHF 0.7 million to CHF 3.9 million for the quarter ended June 30, 2025 [1].
- Net Loss: The company reported a net loss after taxes of CHF 21.2 million for the three months ended June 30, 2025, compared to a net loss of CHF 22.8 million in the same period in 2024 [1].

Pipeline Progress:
- Parkinson’s Disease: ACI-7104.056, AC Immune’s wholly owned a-syn active immunotherapy, showed strong immunogenicity and a favorable safety profile in the ongoing Phase 2 VacSYn trial. Interim results from Part 1 of the trial were reported in April 2025, with further data expected in H2 2025 [1].
- Alzheimer’s Disease: The AD3 cohort in the Phase 2 ABATE trial of ACI-24.060, an anti-Abeta active immunotherapy, is expected to reach 12 months of treatment in December 2025, with interim results expected early 2026 [1].
- NLRP3 Program: ACI-19764, a small molecule inhibitor of NLRP3, has entered IND-enabling studies, highlighting the potential of the early-stage pipeline [1].

Industry Symposium and Upcoming Milestones:
- AC Immune hosted an industry symposium during the AD/PD™ conference, focusing on unlocking active immunotherapy for tailored prevention strategies. The company’s pipeline was featured in multiple presentations at AD/PD™ 2025 [1].
- Anticipated 2025 milestones include interim pharmacodynamic and biomarker results from Part 1 of the VacSYn trial, the AD3 cohort reaching 12 months of treatment in the ABATE trial, and the IND/CTA filing for ACI-19764 [1].

References:
- [1] AC Immune Reports Second Quarter 2025 Financial Results and Provides a Corporate Update, August 5, 2025. Retrieved from https://www.globenewswire.com/news-release/2025/08/05/3127169/0/en/AC-Immune-Reports-Second-Quarter-2025-Financial-Results-and-Provides-a-Corporate-Update.html